Answers are grounded in this paper and cite their sources.
Single-center trial investigates combined hemoperfusion with high-flux dialysis, showing improvements in immune function and quality of life.
Objective This study aimed to investigate the effects of combining hemoperfusion (HP) with high-flux hemodialysis (HFD) on T lymphocyte subsets, mitochondrial health, and clinical outcomes in patients undergoing maintenance hemodialysis (MHD). Methods In this single-center, prospective, self-controlled trial, 20 MHD patients received their regular HFD treatment, with the addition of a single HP session every 2 weeks for 12 sessions. Levels of protein-bound uremic toxins (PBUTs: indoxyl sulphate [IS] and p-cresyl sulphate [PCS]), T lymphocyte subsets (CD3+, CD4+, CD8+), mitochondrial membrane potential (MMP) in T cells, and patient-reported outcomes (SF-36, PSQI, pruritus scale) were assessed before and after the 12 sessions intervention. Results Following a single HP + HFD session, IS and PCS levels decreased significantly ( p < 0.001). However, their pre-perfusion levels at end were not significantly different from baseline. After 12 sessions, increases were observed in the levels of CD3+, CD4+, CD8 + cells, the CD4+/CD8 + ratio, and the percentages of CD3 + MMP, CD4 + MMP, and CD8 + MMP (all p < 0.05). Patients also demonstrated significant improvements in sleep quality (PSQI), uremic pruritus, and overall quality of life (SF-36) (all p < 0.01). Additionally, serum phosphorus and parathyroid hormone levels were significantly reduced after the treatment period. Conclusion After 12 sessions of combined hemoperfusion and high-flux dialysis, we observed significant increases in T lymphocyte subsets (CD3+, CD4+, CD8+, CD4+/CD8 + ratio) and the percentage of T cells with preserved mitochondrial membrane potential. Patients also reported improved sleep quality, reduced pruritus, and better quality of life. However, pre-dialysis levels of protein-bound uremic toxins (indoxyl sulphate and p-cresyl sulphate) of last session were not significantly different from baseline, despite effective clearance immediately after each combined session. Therefore, the observed improvements in immune-related parameters cannot be mechanistically attributed to a sustained reduction in these toxins. Alternative explanations—such as intermittent attenuation of peak toxin concentrations, clearance of unmeasured solutes, or non-specific effects—remain possible. Given the single-arm, observational design, these findings are hypothesis-generating and require confirmation in randomized controlled trials.
No takes yet. Share an insight, caveat, or question.
Zhong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: